Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8965 phase IIb trial in idiopathic pulmonary fibrosis
NL-OMON61477Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of AZD8965 in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in FVC. Started Sep 2026; status: recruiting.
02
Drugs
AZD8965
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON61477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61477.